Cargando…
Genomics of Hairy Cell Leukemia
Hairy cell leukemia (HCL) is a chronic mature B-cell neoplasm with unique clinicopathologic features and an initial exquisite sensitivity to chemotherapy with purine analogs; however, the disease relapses, often repeatedly. The enigmatic pathogenesis of HCL was recently clarified by the discovery of...
Autores principales: | Tiacci, Enrico, Pettirossi, Valentina, Schiavoni, Gianluca, Falini, Brunangelo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455681/ https://www.ncbi.nlm.nih.gov/pubmed/28297625 http://dx.doi.org/10.1200/JCO.2016.71.1556 |
Ejemplares similares
-
Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial
por: Tiacci, Enrico, et al.
Publicado: (2021) -
Recent advances in understanding and managing hairy cell leukemia
por: Roider, Tobias, et al.
Publicado: (2018) -
Gene Expression Profiling of Hairy Cell Leukemia Reveals a Phenotype Related to Memory B Cells with Altered Expression of Chemokine and Adhesion Receptors
por: Basso, Katia, et al.
Publicado: (2004) -
Hairy cell leukemia and COVID-19 adaptation of treatment guidelines
por: Grever, Michael, et al.
Publicado: (2021) -
Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox
por: Robak, Tadeusz, et al.
Publicado: (2021)